Gutiérrez-Grobe Y, Gavilanes-Espinar JG, Masso-Rojas FA,Sánchez-Valle V, Páez-Arenas A, Ponciano-Rodríguez G, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N

Language: English
References: 24
Page: 908-914
PDF size: 129.56 Kb.

ABSTRACT

Background. Endothelial dysfunction has been previously described in metabolic syndrome patients. The levels of circulating endothelial progenitor cells (EPCs) inversely correlates with the incidence of cardiovascular disease. The aim of this study was to investigate the association between NAFLD, metabolic syndrome and EPC levels. Material and methods. A cross-sectional pilot study was performed at a university hospital in Mexico. Two groups of patients without previously known chronic diseases were studied and classified according to the presence of NAFLD. Anthropometric, dietary, and biochemical variables, and circulating EPC number were measured and compared between the groups. Results. Forty subjects were included and classified into two groups: patients with NAFLD (n = 20) and a control group (n = 20). The overall prevalence of insulin resistance and metabolic syndrome was 25% and 17.5%, respectively. EPC levels were found to be higher in the NAFLD group (p ‹ 0.05) as in the patients with insulin resistance (p ‹ 0.01) and metabolic syndrome (p ‹ 0.01). These levels showed correlation with the severity of steatosis. Conclusions. Patients with NAFLD have increased levels of EPC, such levels are associated with the severity of NAFLD. These findings may suggest that these cells may play a role in the early natural history of NAFLD. EPC might be increased in an attempt to repair the endothelial damage resulting from metabolic alterations accompanying NAFLD. Further studies are needed to establish the dynamics of these cells in NAFLD.

REFERENCES

1. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-33.

2. García-Compean D, Jaquez–Quintana JO, González–González JA, Maldonado–Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15: 280-8.

3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.

4. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

5. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gammaglutamyl- transpeptidase levels. Hepatology 2009; 50: 1403-11.

6. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947-53.

7. Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol 2012; 46: 427-30.

8. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25.

9. Rodríguez T, Malvezzi M, Chatenoud L, et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970–2000. Heart 2006; 92: 453.

10. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420-5.

11. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.

12. Liu J, Musani SK, Bidulescu A, et al. Fatty liver, abdominal tissue and atherosclerotic calcification in African Americans: The Jackson Heart Study. Atherosclerosis 2012; 224: 521-5.

13. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.

14. Ben-Shoshan J, George J. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: from experimental models to human trials. Pharmacol Ther 2007; 15: 25-36.

15. Mayr M, Niederseer D, Niebauer J. From bench to bedside: what physicians need to know about endothelial progenitor cells. Am J Med 2011: 489-97.

16. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.

17. oHamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-15.

18. Ahmed MH, Barakat A, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: Has the time come for cardiologists to be hepatologists? J Obes 2012. Doi: 10.1155/2012/483135.

19. Kucukazman M, Ata N, Yavuz B, et al. Evaluation of early arteriosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25: 147-51.

20. Jung C, Fischer N, et al. Endothelial progenitor cells in adolescents: impact of overweight, age, smoking, sport and cytokines in younger age. Clin Res Cardiol 2009; 98: 179-88.

21. Satoh M, Ishikawa Y, Takahashi Y, Itoh T, Minami Y, Nakamura M. Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis 2010; 211: 297-302.

22. Vignera SL, Condorelli R, Vicari E, d’Agata R, Calogero AE. Circulating endothelial progenitor cells and endothelial microparticles in patients with arterial erectile dysfunction and metabolic syndrome. J Androl 2012: 3: 202-9.

23. Devaraj S, Jialal I. Dysfunctional Endothelial Progenitor Cells in Metabolic. Syndrome. Exp diab Res 2012; 2012: 1-5.

24. Chiang C-H, Huang P-H, Chung F-P, Chen Z-Y, Leu H-B, et al. Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. PLoS ONE 2012: 7: e31799.